MAP2K7 and lung adenocarcinoma: Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in &lt;i&gt;BRAF&lt;/i&gt; V600E-mutated lung adenocarcinoma: a case report.